Repros Therapeutics Inc. (Nasdaq: RPRX) reported positive clinical data for Proellex to treat severe menstrual bleeding from uterine fibroids sending the stock price soaring 80 cents to $3.05.
Repros Therapeutics reports positive data
April 14, 2016 at 12:02 PM EDT
